BOT - Anything but charting, page-9127

sheesh. Quite the reaction, sorry to have hit a nerve, not my intention.

perhaps I should rephrase the question: As we enter the new FY, is there a view that the persistent selling pressure since the FDA announcement is a combination of profit taking due to the new FY and the newly issued stock overhang?

to be clear, I’m all in on the fundamentals. My question is technical. Like many, I have Owned the stock for over 5 years, so like you, the daily price action is not my concern. Rather, I am curious re; the pressure on the stock. There was argument that the approval was not priced in. I was unsure, thinking it might have been. But I concede that it probably wasn’t and what we are seeing now is perhaps what I suggest above. Just curious on consensus. It was a genuine question, so I think it’s you that needs to calm down a bit.